Mushroom research and cancer treatment are two different things. A handful of mushroom compounds, mainly from turkey tail and reishi, have been studied in human clinical trials as an add-on to standard chemotherapy or radiation, not as a replacement for it. The strongest human data comes from Japan, where a turkey tail extract called PSK has been used for decades alongside surgery and chemotherapy for certain cancers. No mushroom product, including PSK, is approved by the FDA to treat, cure, or prevent any cancer in the United States.
Read This First: Safety Warnings That Come Before Anything Else
The National Center for Complementary and Integrative Health (NCCIH) warns that some herbal supplements can make chemotherapy drugs less effective or interact with them in harmful ways. This is true even for supplements that seem harmless because they are sold over the counter.
- Never use a mushroom supplement to replace or delay a recommended cancer treatment. The National Cancer Institute (NCI) is direct about this: no single food, herb, or supplement has been proven to cure, control, or prevent the return of cancer.
- Tell every doctor and pharmacist involved in your care about any mushroom supplement you take, including the brand, dose, and how often. This matters most during active chemotherapy, radiation, or before surgery.
- Stop and ask a clinician first if you notice unusual bruising, bleeding, jaundice (yellowing skin or eyes), or a rash after starting a mushroom supplement. These can signal a liver problem or a drug interaction and need prompt medical attention.
- Supplement quality is not guaranteed. The FDA does not routinely verify that a mushroom supplement contains what the label claims, in the amount claimed. Product variability is a documented limitation even in the research base itself.
Adjunctive Research vs. Cancer Treatment: The Difference That Matters
“Adjunctive” means used alongside standard treatment, not instead of it. In the studies with the most human evidence, patients received chemotherapy or radiation exactly as their oncologist prescribed, and a mushroom-derived compound was added on top. The research question was never “can this mushroom replace chemotherapy.” It was “does adding this compound to standard treatment change outcomes like survival, recurrence, or side effects.”
That distinction is why NCI’s own patient materials describe medicinal mushrooms as a type of complementary and alternative medicine (CAM), a category that includes supplements, botanicals, and mind-body practices used to support standard cancer care, not to substitute for it.
Species and Compounds With the Most Clinical Evidence
Most mushroom and cancer research falls into cell studies (in vitro) or animal studies, which cannot show what happens in a person. Only a small number of species have been tested in actual human clinical trials with cancer patients. Here is how the two most-studied species compare, based on NCI’s Medicinal Mushrooms review.
Turkey Tail (Trametes versicolor) and PSK
- What it is: PSK (polysaccharide-K, also called Krestin) is a purified extract from turkey tail mushroom, developed and used as an approved adjunct to cancer treatment in Japan for more than 30 years.
- Gastric cancer: In a study of 262 patients after stomach cancer surgery, those who received chemotherapy plus PSK had a higher 5-year disease-free survival rate than chemotherapy alone (70.7% vs. 59.4%). A later analysis pooling more than 8,000 patients across eight trials found a statistically significant survival benefit when PSK was added to chemotherapy.
- Colorectal cancer: A pooled analysis of three randomized trials involving 1,094 patients found better 5-year disease-free and overall survival in patients who received PSK alongside chemotherapy.
- Lung cancer: A review of PSK studies found that patients who received it alongside chemotherapy or radiation improved in at least one measure, such as immune markers, weight, symptoms, or survival, more often than those who did not.
- Safety: NCI notes that PSK has a well-established safety record in Japan with few reported side effects, based on decades of clinical use.
This is genuinely one of the better-studied natural compounds in oncology supportive care research. It is still not an approved cancer treatment in the United States, and none of these trials tested turkey tail or PSK as a stand-alone therapy without chemotherapy. Our turkey tail mushroom research and safety profile covers the compound, dosing studied in trials, and quality concerns in more depth.
Reishi (Ganoderma lucidum)
- What the human studies measured: NCI is explicit that there are no human studies of reishi with measured cancer outcomes like survival or recurrence. Most human trials measured immune markers instead, such as natural killer cell activity or cytokine levels, and results were mixed.
- One relevant finding: In a 12-month study of 123 patients with colorectal adenomas (precancerous polyps), those who took a cultured reishi mycelia extract had a decrease in adenoma count and size, compared with an increase in untreated patients. This is a meaningful signal, but adenoma shrinkage is not the same as a cancer outcome, and this was one study, not a body of confirmed evidence.
- Lung cancer immune studies: A 12-week trial in 30 evaluable patients with advanced lung cancer found no significant change in most immune markers when reishi polysaccharide extract was added to chemotherapy or radiation.
Reishi’s laboratory and animal data (cell growth arrest, effects on tumor blood vessel signaling, drug-resistance mechanisms) are more extensive than its human clinical data. That gap between promising lab findings and thin human trial results is common in this field, and it is exactly why the two should never be presented as equivalent. See our reishi mushroom research profile for the full compound and safety breakdown.
Other species
Maitake, shiitake, and other culinary and medicinal mushrooms have laboratory and animal research related to beta-glucans and immune signaling, but they do not have the volume of randomized human cancer trials that turkey tail and, to a lesser extent, reishi have. Preliminary lab evidence is not the same as clinical proof, and it should not be marketed as such.
Clinical vs. Preclinical Evidence, Side by Side
Use this quick reference to judge any mushroom-and-cancer claim you encounter, including on this site.
- In vitro (cell/lab) evidence: Mushroom compounds are applied directly to cancer cells in a dish. This can show a mechanism, such as triggering cell death, but cells in a dish behave nothing like a tumor inside a living person. This is the earliest and weakest form of evidence.
- Animal (preclinical) evidence: Mushroom extracts are given to mice or rats with induced tumors. This adds information about how a compound behaves in a living system, but animal metabolism and dosing do not reliably predict human results.
- Human observational studies: Researchers track outcomes in people already using a supplement, without a controlled comparison group matched exactly. Useful for spotting patterns, but confounding factors (diet, other treatments, disease stage) can distort the picture.
- Human randomized controlled trials (RCTs): Patients are randomly assigned to receive the mushroom compound plus standard treatment, or standard treatment alone, and outcomes are compared. This is the strongest evidence type discussed here, and it is what the PSK gastric and colorectal cancer trials used.
Our evidence hierarchy guide walks through how we grade every claim on this site using this same framework.
Why an Over-the-Counter Mushroom Supplement Is Not a Cancer Treatment
Even when a compound like PSK has real trial data behind it, that does not make the mushroom capsule on a store shelf equivalent to what was studied. Several gaps matter:
- Different formulations. PSK is a specific, standardized pharmaceutical-grade extract manufactured under strict conditions in Japan. A general “turkey tail” supplement bought online is very unlikely to match its concentration, purity, or manufacturing process.
- No FDA approval as a drug. In the U.S., medicinal mushrooms are regulated as dietary supplements, not drugs. The FDA does not evaluate supplements for effectiveness before they reach shelves, and it does not require proof they work the way the label implies.
- Lot-to-lot variability. NCI notes that even under FDA manufacturing rules, ingredient amounts in supplements can vary between batches and brands, and labels are not guaranteed to reflect what’s actually inside.
- Trials studied specific doses in specific cancers. The gastric and colorectal cancer trials used defined doses (commonly PSK 3 grams per day) in specific patient populations who were also receiving chemotherapy. Applying those results to a different cancer type, a different dose, or use without chemotherapy is not supported by the data.
Our supplement quality standards and testing guide explains what independent testing and certification can and can’t tell you about a product on the shelf.
What Responsible Integration With Oncology Care Looks Like
NCI and NCCIH both frame this the same way: complementary approaches, including mushroom supplements, are a conversation to have with the treatment team, not a decision to make alone. A simple checklist for that conversation:
- Bring the exact product name, brand, and dose to your oncologist or oncology pharmacist before starting anything, not after.
- Ask directly whether the specific compound has known interactions with your chemotherapy, radiation, targeted therapy, or immunotherapy regimen.
- Ask whether timing matters, for example, whether a supplement needs to be paused around surgery or specific infusion dates.
- Report any new bruising, bleeding, digestive changes, or skin or eye yellowing right away rather than waiting for the next appointment.
- Treat “natural” and “over the counter” as separate questions from “safe with my treatment.” They are not the same thing.
Evidence Limits, Honestly Stated
- No trial reviewed here compared a mushroom compound against a placebo in a way that also isolated it as a stand-alone cancer treatment. All positive results occurred with the mushroom compound added to standard chemotherapy or radiation.
- Most of the higher-quality PSK trials were conducted decades ago in Japan, often in gastric and colorectal cancer specifically. Results in these cancers should not be assumed to apply to other cancer types.
- Reishi’s human evidence base is thinner than turkey tail’s and mostly measures immune markers, not survival or recurrence.
- Mechanisms seen in cell and animal studies frequently do not translate into meaningful benefit in people. A compound “killing cancer cells in a dish” is not evidence it will help a patient.
- Publication and language bias are a known limitation; much of the older Japanese PSK literature is harder to independently verify through Western databases than more recent, English-language trials.
Groups Who Need Extra Caution
- Anyone currently in active chemotherapy, radiation, or targeted therapy, because of documented interaction risk with herbal and mushroom supplements.
- Anyone with a scheduled surgery, since some supplements affect bleeding or immune response and may need to be paused beforehand.
- People with liver or kidney conditions, since concentrated mushroom extracts are processed through these organs and safety data in this group is limited.
- People taking immunosuppressant medication, such as after an organ transplant, because immune-stimulating mushroom compounds could theoretically work against those medications. This has not been well studied and is a reason for direct clinician review, not self-management.
- Pregnant or breastfeeding people, because safety data for concentrated mushroom extracts in pregnancy is not established.
Frequently Asked Questions
Can mushroom supplements cure or shrink cancer on their own?
No. No mushroom supplement is FDA-approved to treat, cure, or prevent cancer, and the human trials with the strongest results tested mushroom compounds added to standard treatment, not used in place of it.
Which mushroom has the best cancer-related human evidence?
Turkey tail, specifically the extract PSK, has the most human randomized trial data, mainly in gastric and colorectal cancer as an add-on to chemotherapy. Reishi’s human data is weaker and mostly limited to immune markers rather than survival outcomes.
Is it safe to take a mushroom supplement during chemotherapy?
This should be decided with your oncology team, not on your own. NCCIH specifically warns that some herbal supplements can reduce chemotherapy’s effectiveness or interact with it in harmful ways, so any supplement needs to be disclosed and reviewed before you start it.
Why do lab and animal studies show stronger results than human trials?
Cell and animal studies test a compound under controlled conditions that don’t reflect how a whole human body absorbs, processes, and responds to it. They are useful for identifying a possible mechanism worth testing further, but they consistently overstate real-world effect compared to human randomized trials.
Educational Disclaimer
This article is for general educational purposes only. It is not medical advice, and it is not a recommendation to start, stop, or change any cancer treatment or supplement. Mushroom compounds discussed here have been studied only as additions to standard oncology care under clinical trial conditions, not as replacements for it. Always talk with your oncologist, treating physician, or pharmacist before adding any supplement, including mushroom products, to a cancer treatment plan, and seek prompt medical attention for any new or worsening symptoms during treatment.